دورية أكاديمية
أعرض في EDS

Id-1, Id-2, and Id-3 co-expression correlates with prognosis in stage I and II lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy.

التفاصيل البيبلوغرافية
العنوان: Id-1, Id-2, and Id-3 co-expression correlates with prognosis in stage I and II lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy.
المؤلفون: Antonângelo L; Department of Pathology, University of Sao Paulo, Sao Paulo 01246903,Brazil., Tuma T; Department of Pathology, University of Sao Paulo, Sao Paulo 01246903,Brazil., Fabro A; Department of Pathology, University of Sao Paulo, Sao Paulo 01246903,Brazil., Acencio M; Pulmonary Division, Heart Institute Clinics Hospital, University of Sao Paulo, Sao Paulo 01246903, Brazil., Terra R; Pulmonary Division, Heart Institute Clinics Hospital, University of Sao Paulo, Sao Paulo 01246903, Brazil., Parra E; Department of Pathology, University of Sao Paulo, Sao Paulo 01246903,Brazil., Vargas F; Pulmonary Division, Heart Institute Clinics Hospital, University of Sao Paulo, Sao Paulo 01246903, Brazil., Takagaki T; Pulmonary Division, Heart Institute Clinics Hospital, University of Sao Paulo, Sao Paulo 01246903, Brazil., Capelozzi V; Department of Pathology, University of Sao Paulo, Sao Paulo 01246903,Brazil vcapelozzi@lim05.fm.usp.br.
المصدر: Experimental biology and medicine (Maywood, N.J.) [Exp Biol Med (Maywood)] 2016 Jun; Vol. 241 (11), pp. 1159-68. Date of Electronic Publication: 2016 Feb 10.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Sage Country of Publication: England NLM ID: 100973463 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-3699 (Electronic) Linking ISSN: 15353699 NLM ISO Abbreviation: Exp Biol Med (Maywood) Subsets: MEDLINE
أسماء مطبوعة: Publication: Nov. 2012- : London : Sage
Original Publication: Maywood, NJ : The Society, c2001-
مواضيع طبية MeSH: Adenocarcinoma/*diagnosis , Adenocarcinoma/*pathology , Antineoplastic Agents/*therapeutic use , Biomarkers, Tumor/*analysis , Delta Sleep-Inducing Peptide/*analogs & derivatives , Inhibitor of Differentiation Protein 1/*analysis , Inhibitor of Differentiation Proteins/*analysis , Lung Neoplasms/*diagnosis , Lung Neoplasms/*pathology , Neoplasm Proteins/*analysis, Adenocarcinoma/drug therapy ; Adenocarcinoma/surgery ; Adenocarcinoma of Lung ; Adult ; Aged ; Aged, 80 and over ; Biometry ; Chemotherapy, Adjuvant ; Delta Sleep-Inducing Peptide/analysis ; Female ; Humans ; Immunohistochemistry ; Lung Neoplasms/drug therapy ; Lung Neoplasms/surgery ; Male ; Middle Aged ; Neoplasm Grading ; Neovascularization, Pathologic/pathology ; Prognosis
مستخلص: Inhibitors of DNA binding/inhibitors of differentiation (Id) protein family have been shown to be involved in carcinogenesis. However, the roles of Id during lung adenocarcinoma (ADC) progression remain unclear. Eighty-eight ADC samples were evaluated for Id-1,2,3 level and angiogenesis (CD 34 and VEGF microvessel density) by immunohistochemistry and morphometry. The impact of these markers was tested on follow-up until death or recurrence. A significant difference between tumor and normal tissue was found for Id-1,2,3 expression (P < 0.01). In addition, high levels of nuclear Id-1 were associated with higher angiogenesis in the tumor stroma (P < 0.01). Equally significant was the association between patients in T1-stage and low cytoplasmic Id-2, as well as patients in stage-IIb and low Id-3. High cytoplasm Id-3 expression was also directly associated to lymph nodes metastasis (P = 0.05). Patients at stages I to III, with low Id-1 and Id-3 cytoplasm histoscores showed significant long metastasis-free survival time than those with high Id-1 or Id-3 expression (P = 0.04). Furthermore, high MVD-CD34 and MVD-VEGF expression were associated with short recurrence-free survival compared to low MVD-CD34 and MVD-VEGF expressions (P = 0.04). Cox model analyses controlled for age, lymph node metastasis, and adjuvant treatments showed that nuclear Id-1, cytoplasmic Id-3, and MVD-CD34 were significantly associated with survival time. Median score for nuclear Id-1 and cytoplasmic Id-3 divided patients in two groups, being that those with increased Id-1 and Id-3 presented higher risk of death. Ids showed an independent prognostic value in patients with lung ADC, regardless of disease stage. Id-1 and Id-3 should be considered new target candidates in the development of personalized therapy in lung ADC.
(© 2016 by the Society for Experimental Biology and Medicine.)
References: Br J Cancer. 2007 Nov 19;97(10):1409-15. (PMID: 18000500)
Clin Cancer Res. 2011 Jun 15;17(12):4155-66. (PMID: 21540238)
Nucleic Acids Res. 1994 Mar 11;22(5):749-55. (PMID: 8139914)
Clin Cancer Res. 2004 Nov 15;10(22):7475-83. (PMID: 15569977)
Nature. 1999 Oct 14;401(6754):670-7. (PMID: 10537105)
Am J Pathol. 1999 Sep;155(3):815-22. (PMID: 10487839)
Oncogene. 2003 Oct 9;22(44):6946-53. (PMID: 14534543)
J Thorac Oncol. 2007 Aug;2(8):706-14. (PMID: 17762336)
Br J Cancer. 2008 Nov 18;99(10):1557-63. (PMID: 19002177)
Cancer Biol Ther. 2002 Mar-Apr;1(2):91-6. (PMID: 12170780)
J Oncol. 2010;2010:856105. (PMID: 20414347)
Arch Pathol Lab Med. 1985 Aug;109(8):716-21. (PMID: 3893381)
Cancer Res. 2001 Dec 15;61(24):8803-10. (PMID: 11751402)
Proc Natl Acad Sci U S A. 1994 May 24;91(11):4985-8. (PMID: 8197168)
Hum Pathol. 2010 Feb;41(2):239-48. (PMID: 19828174)
J Thorac Oncol. 2009 May;4(5):568-77. (PMID: 19357537)
J Thorac Oncol. 2015 May;10(5):806-14. (PMID: 25629637)
J Natl Cancer Inst. 1990 Jan 3;82(1):4-6. (PMID: 1688381)
Mol Cell Biol. 1998 Aug;18(8):4577-88. (PMID: 9671467)
Cell Growth Differ. 1995 Jul;6(7):837-43. (PMID: 7547505)
Int J Cancer. 2006 Mar 15;118(6):1356-63. (PMID: 16184548)
Oncol Rep. 2010 Feb;23(2):321-8. (PMID: 20043091)
Cancer Res. 2006 Nov 15;66(22):10870-7. (PMID: 17108123)
Trends Cell Biol. 1998 Feb;8(2):58-65. (PMID: 9695810)
J Transl Med. 2013 May 29;11:132. (PMID: 23714001)
Lung Cancer. 2001 Aug-Sep;33(2-3):229-39. (PMID: 11551418)
Cancer Lett. 2006 Dec 8;244(2):203-10. (PMID: 16469432)
Cancer Cell. 2003 Jun;3(6):525-30. (PMID: 12842081)
Mol Cell Biol. 1998 Apr;18(4):2371-81. (PMID: 9528806)
Mol Cancer. 2010 May 28;9:130. (PMID: 20509890)
Lung Cancer. 2011 Mar;71(3):306-11. (PMID: 20709421)
Gynecol Oncol. 2013 Feb;128(2):391-6. (PMID: 23142075)
Am J Surg Pathol. 2010 Aug;34(8):1155-62. (PMID: 20551825)
Braz J Med Biol Res. 2013 Jan;46(1):21-31. (PMID: 23314337)
Mod Pathol. 2006 Jul;19(7):931-41. (PMID: 16575399)
Acta Biochim Biophys Sin (Shanghai). 2011 Oct;43(10):796-804. (PMID: 21880603)
Nat Rev Cancer. 2005 Aug;5(8):603-14. (PMID: 16034366)
Ann Thorac Surg. 2007 Dec;84(6):1818-24. (PMID: 18036891)
Hum Pathol. 2012 May;43(5):675-83. (PMID: 21992818)
Pathol Oncol Res. 2009 Mar;15(1):91-6. (PMID: 18752043)
Cancer Sci. 2005 Nov;96(11):784-90. (PMID: 16271072)
J Thorac Cardiovasc Surg. 2009 Oct;138(4):849-58. (PMID: 19660370)
Oncogene. 2001 Dec 20;20(58):8334-41. (PMID: 11840326)
Clin Cancer Res. 2008 Apr 15;14(8):2318-25. (PMID: 18413820)
Int J Oncol. 2005 Feb;26(2):319-27. (PMID: 15645115)
فهرسة مساهمة: Keywords: Lung adenocarcinoma; angiogenesis; immunohistochemistry; inhibitors of DNA binding/inhibitors of differentiation; morphometry; prognosis
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Biomarkers, Tumor)
0 (ID1 protein, human)
0 (Inhibitor of Differentiation Protein 1)
0 (Inhibitor of Differentiation Proteins)
0 (Neoplasm Proteins)
147785-34-0 (ID3 protein, human)
65908-45-4 (delta sleep-inducing peptide, N-Tyr-)
69431-45-4 (Delta Sleep-Inducing Peptide)
تواريخ الأحداث: Date Created: 20160213 Date Completed: 20170606 Latest Revision: 20190221
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC4950313
DOI: 10.1177/1535370216632623
PMID: 26869608
قاعدة البيانات: MEDLINE
الوصف
تدمد:1535-3699
DOI:10.1177/1535370216632623